{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:46:05Z","timestamp":1782603965064,"version":"3.54.5"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,11,15]]},"DOI":"10.18632\/oncotarget.2533","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:37:14Z","timestamp":1442360234000},"page":"10732-10744","source":"Crossref","is-referenced-by-count":11,"title":["Simultaneous targeting of PI3K\u03b4 and a PI3K\u03b4-dependent MEK1\/2-Erk1\/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia"],"prefix":"10.18632","volume":"5","author":[{"given":"Xiang","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben-shang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Children's Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Yang","sequence":"additional","affiliation":[{"name":"Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-xia","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Shanghai Jiaotong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Children's Hospital of Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Liang","sequence":"additional","affiliation":[{"name":"Xcovery, LLC, West Palm Beach, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-hua","family":"Meng","sequence":"additional","affiliation":[{"name":"Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,9,26]]},"reference":[{"issue":"9617","key":"1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Look","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/jcp.42.12.1253","article-title":"Bone marrow fibrosis in childhood acute lymphoblastic leukaemia","volume":"42","author":"Reid","year":"1989","journal-title":"Journal of clinical pathology"},{"issue":"3","key":"3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0002-9343(76)90752-X","article-title":"Bone marrow necrosis","volume":"60","author":"Wheby","year":"1976","journal-title":"The American journal of medicine"},{"issue":"1","key":"4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V67.1.1.1","article-title":"Lineage promiscuity in hemopoietic differentiation and leukemia","volume":"67","author":"Molgaard","year":"1986","journal-title":"Blood"},{"issue":"6","key":"5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.2287","article-title":"The Pediatric Cancer Genome Project","volume":"44","author":"Evans","year":"2012","journal-title":"Nature genetics"},{"issue":"7","key":"6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Sawyers","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"7","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1124\/jpet.110.167940","article-title":"WJD008, a dual phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant","volume":"334","author":"Ding","year":"2010","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"3","key":"8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jbior.2012.04.002","article-title":"PI3K keeps the balance between metabolism and cancer","volume":"52","author":"Hirsch","year":"2012","journal-title":"Advances in biological regulation"},{"issue":"14","key":"9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1101\/gad.191973.112","article-title":"The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis","volume":"26","author":"Zhao","year":"2012","journal-title":"Genes & development"},{"issue":"1","key":"10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.gastro.2011.05.010","article-title":"Targeting PI3K signaling as a therapeutic approach for colorectal cancer","volume":"141","author":"Shivdasani","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/2159-8290.CD-11-0249","article-title":"PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic","volume":"1","author":"Rommel","year":"2011","journal-title":"Cancer discovery"},{"issue":"2","key":"12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Giese","year":"2011","journal-title":"Blood"},{"issue":"12","key":"13","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Johnson","year":"2010","journal-title":"Blood"},{"issue":"8","key":"14","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Lannutti","year":"2012","journal-title":"Blood"},{"issue":"7","key":"15","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1074\/mcp.M900568-MCP200","article-title":"Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor","volume":"9","author":"Goillot","year":"2010","journal-title":"Molecular & cellular proteomics : MCP"},{"issue":"10","key":"16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nmeth.1506","article-title":"A human MAP kinase interactome","volume":"7","author":"Ideker","year":"2010","journal-title":"Nature methods"},{"issue":"4","key":"17","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/MCB.20.4.1448-1459.2000","article-title":"A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling","volume":"20","author":"Schlessinger","year":"2000","journal-title":"Molecular and cellular biology"},{"issue":"29","key":"18","doi-asserted-by":"crossref","first-page":"19925","DOI":"10.1074\/jbc.M600482200","article-title":"Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops","volume":"281","author":"Kholodenko","year":"2006","journal-title":"The Journal of biological chemistry"},{"issue":"6","key":"19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Largaespada","year":"2014","journal-title":"Oncotarget"},{"key":"20","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"Normanno","year":"2012","journal-title":"Expert opinion on therapeutic targets"},{"issue":"1","key":"21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1042\/BST20110609","article-title":"Cross-talk between mitogenic Ras\/MAPK and survival PI3K\/Akt pathways: a fine balance","volume":"40","author":"Kholodenko","year":"2012","journal-title":"Biochemical Society transactions"},{"issue":"12","key":"22","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.18632\/oncotarget.1463","article-title":"Loss of E-cadherin activates EGFR-MEK\/ERK signaling, which promotes invasion via the ZEB1\/MMP2 axis in non-small cell lung cancer","volume":"4","author":"Cha","year":"2013","journal-title":"Oncotarget"},{"issue":"9","key":"23","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood-2009-06-222943","article-title":"PI3K\/p110{delta} is a novel therapeutic target in multiple myeloma","volume":"116","author":"Munshi","year":"2010","journal-title":"Blood"},{"issue":"2","key":"24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nchembio.293","article-title":"The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Williams","year":"2010","journal-title":"Nature chemical biology"},{"key":"25","article-title":"A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth","author":"Meng","year":"2013","journal-title":"Acta pharmacologica Sinica"},{"issue":"7205","key":"26","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis","volume":"454","author":"Zhao","year":"2008","journal-title":"Nature"},{"issue":"24","key":"27","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1182\/blood-2009-06-225474","article-title":"Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma","volume":"114","author":"Guo","year":"2009","journal-title":"Blood"},{"issue":"3","key":"28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Bonavida","year":"2007","journal-title":"Cancer research"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/2159-8290.CD-13-0611","article-title":"Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling","volume":"4","author":"Rosen","year":"2014","journal-title":"Cancer discovery"},{"key":"30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/msb.2009.19","article-title":"Systems-level interactions between insulin-EGF networks amplify mitogenic signaling","volume":"5","author":"Kholodenko","year":"2009","journal-title":"Molecular systems biology"},{"issue":"Pt 1","key":"31","first-page":"55","article-title":"A new mechanism for the regulation of Gab1 recruitment to the plasma membrane","volume":"122","author":"Schaper","year":"2009","journal-title":"Journal of cell science"},{"issue":"2","key":"32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/MCB.01318-07","article-title":"Signal strength dictates phosphoinositide 3-kinase contribution to Ras\/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1\/Shp2 recruitment: consequences for resistance to epidermal growth factor receptor inhibition","volume":"28","author":"Raynal","year":"2008","journal-title":"Molecular and cellular biology"},{"issue":"32","key":"33","doi-asserted-by":"crossref","first-page":"33759","DOI":"10.1074\/jbc.M402055200","article-title":"Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK\/MAPK signal transduction pathway","volume":"279","author":"Tsuruo","year":"2004","journal-title":"The Journal of biological chemistry"},{"issue":"1","key":"34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.canlet.2012.11.031","article-title":"Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer","volume":"330","author":"Huang","year":"2013","journal-title":"Cancer letters"},{"issue":"6484","key":"35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/370071a0","article-title":"PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase","volume":"370","author":"Blenis","year":"1994","journal-title":"Nature"},{"issue":"22","key":"36","doi-asserted-by":"crossref","first-page":"19382","DOI":"10.1074\/jbc.M200732200","article-title":"ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase","volume":"277","author":"Cantley","year":"2002","journal-title":"The Journal of biological chemistry"},{"issue":"14","key":"37","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","article-title":"antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models","volume":"15","author":"Friedman","year":"2009","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"12","key":"38","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.18632\/oncotarget.747","article-title":"Identification and characterization of a novel chemotype MEK inhibitor able to alter the phosphorylation state of MEK1\/2","volume":"3","author":"Nakamura","year":"2012","journal-title":"Oncotarget"},{"issue":"9","key":"39","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Abate-Shen","year":"2008","journal-title":"J Clin Invest"},{"issue":"12","key":"40","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Padera","year":"2008","journal-title":"Nat Med"},{"issue":"10","key":"41","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"Maksimovic-Ivanic","year":"2012","journal-title":"Oncotarget"},{"issue":"1","key":"42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2013.08.046","article-title":"Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer","volume":"342","author":"Meng","year":"2014","journal-title":"Cancer letters"},{"key":"43","article-title":"DW09849, a selective PI3K inhibitor, Prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110alpha (H1047R)","author":"Meng","year":"2013","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"3","key":"44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nchembio0310-244b","article-title":"The p110delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors","volume":"6","author":"Williams","year":"2010","journal-title":"Nature chemical biology"},{"issue":"9","key":"45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bcp.2012.01.019","article-title":"Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR","volume":"83","author":"Meng","year":"2012","journal-title":"Biochemical pharmacology"},{"issue":"6","key":"46","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s10637-010-9481-8","article-title":"The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells","volume":"29","author":"Meng","year":"2011","journal-title":"Invest New Drug"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T10:29:37Z","timestamp":1599560977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,26]]},"references-count":46,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2014,11,15]]}},"alternative-id":["2533","25313141"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2533","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,26]]}}}